Novo Nordisk India has announced price reductions for its original and well-established semaglutide injections for patients living with type 2 diabetes and obesity or overweight. Effective April 1, 2026, the price of the starting dose of Ozempic® will be reduced by 36%, while that of the starting dose of Wegovy® will be reduced by 48% in India.
Ozempic® (0.25 mg) and Wegovy® (0.25 mg) will now be available in India at an effective daily price of Rs 202 or a weekly price of Rs. 1,415 inclusive of taxes. This is done to make these innovative therapies, that are supported by robust clinical evidence and high scientific standards, more accessible to a larger section of people living with diabetes and obesity in India.
Ozempic® is the only GLP-1 RA with the broadest range of benefits for people with type 2 diabetes (PwT2D), proven to provide significant glycaemic control, compelling weight loss, along with risk reduction of cardiovascular and kidney events in PwT2D.
Wegovy® delivers quality and sustainable weight loss with proven cardiovascular benefits in people living with overweight/obesity. Both are indicated adjunct to diet and exercise and are prescription only medications that should be used in line with their approved indication under the supervision of a healthcare professional.
Novo Nordisk’s semaglutide, the active pharmaceutical ingredient in Wegovy® and Ozempic®, is backed by 50+ clinical trials, 49 million patient years of exposure, and extensive real-world evidence. Both therapies are manufactured using rDNA technology, are available in a pen device with established safety standards, and follow a robust nation-wide cold chain management process.
